Overall survival after palliative thoracic radiotherapy for locally advanced non-small cell lung cancer not suitable for curative intended treatment

O. Hansen, J. Kenholm, T. Schytte

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review


Introduction: A number of patients with medical inoperable local/locally advanced NSCLC in PS0-2 are not suitable for curative intended radiotherapy (RT), but may be offered palliative RT towards the thoracic tumor (pall-TRT) to obtain tumor reduction to prolong overall survival (OS). Objectives: To study OS in patients who had received pall-TRT 30 Gy/10 Fractions (F). Methods: From 316 patients with lung cancer who received pall-TRT 30 Gy/10 F 2005-2010, a cohort was chosen of 71 patients who fulfilled the following inclusion criteria: Histologically/cytologically proven NSCLC, stage I-III, and WHO PS0-2. Results: The median age was 70.7 years(y). 49% had squamous cell carcinoma. Stages: I-II 15(21%), IIIA32 (45%), IIIB 29(41%). PS0-1 35(41%), PS2 36(51%). 31(44%) received chemotherapy. The reasons for not receiving curatively intend RT was given as: large radiation portals 44 (62%), location of tumor 13 (18%), poor condition of patient 19 (27%), high age 8 (11%), poor lung function 9 (13%), unspecified reason 27 (38%). Survival for all patients: was median 9 months, 1y 36%, 2y 17%, 3y 11%, 4y 10%, and 5y 8%. A trend for better survival was seen for PS 0-1. In Cox analysis neither histology, use of chemotherapy, PS, stage nor gender had a statistical significant impact on OS, while the exclusion criteria 'large radiation portal' and age >70 y were associated with better OS. Conclusions: Patients with stage I-III NSCLC not suitable for curative intended treatment may achieve long time survival. (Figure Presented).
TidsskriftSupportive Care in Cancer
Udgave nummerSUPPL. 1
Sider (fra-til)S317
Antal sider1
StatusUdgivet - 2015
BegivenhedMASCC/ISOO International Symposium - Bella Center, Copenhagen, Danmark
Varighed: 25. jun. 201527. jun. 2015


SeminarMASCC/ISOO International Symposium
LokationBella Center


  • *overall survival *radiotherapy *non small cell lung cancer *neoplasm human patient survival radiation chemotherapy histology lung function thorax tumor squamous cell carcinoma lung cancer gender world health organization